Life Saving Drugs Program – funding for Aldurazyme® (laronidase-rch)

Aldurazyme® will be added to the Life Saving Drugs Program so that people with a very rare enzyme deficiency disorder can obtain it at heavily subsidised prices.

Page last updated: 08 May 2007

PDF printable version of Life Saving Drugs Program – funding for Aldurazyme® (laronidase-rch) (PDF 79 KB)

Why is this important?

  • This measure will add Aldurazyme® (laronidase-rch) to the Life Saving Drugs Program for the treatment of mucopolysaccharidosis type 1 (MPS1); an extremely rare enzyme deficiency disorder which affects many body functions. MPS1 results in severe physical deformities, breathing difficulties and a reduced life expectancy.
  • The Pharmaceutical Benefits Advisory Committee found that Aldurazyme® is an effective treatment for this serious medical condition.

Who will benefit?

  • It is anticipated that around eight to 12 people will be treated with Aldurazyme® over the first few years of funding.
  • It is expected that Aldurazyme® will extend the lives of the people who qualify for treatment and improve their quality of life.

What funding is the Government committing to the initiative?

  • The Government has provided funding of $16.4 million over four years.

What have we done in the past?

  • There are two other drugs funded under the Life Saving Drugs Program that are also used to treat very rare enzyme disorders.
  • Cerezyme® (Imiglucerase) is used for the treatment of Gaucher disease, and Fabrazyme® and Replagal® (agalsidase) for Fabry disease.
  • $30.8 million was provided in 2005-06 under the Life Saving Drugs Program.

When will the initiative conclude?

  • Funding will be ongoing.


Guidelines For Eligibility To Receive Treatment Of Mucopolysaccharidosis Type 1 (MPS1) With Laronidase Through The Life Saving Drugs Program (PDF 33 KB)

In this section